Table 1.
Demographic Data and Results of Strongyloides Serological Testing
| All (N = 149) | Strongyloides Positive (n = 14) | Strongyloides Negative (n = 135) | |||||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | P | |
| Age in years (median) | 149 | 58 years | 14 | 9.4 | 135 | 90.6 | |
| Sex | .95 | ||||||
| Male | 92 | 63 | 9 | 9.8 | 83 | 90.2 | |
| Female | 53 | 37 | 5 | 9.4 | 48 | 90.6 | |
| Nationality | .90 | ||||||
| African | 5 | 3 | 0 | 0 | 5 | 100 | |
| Asian | 22 | 15 | 3 | 14 | 19 | 86 | |
| Latin | 116 | 78 | 11 | 9 | 105 | 91 | |
| Middle Eastern | 5 | 3 | 0 | 0 | 5 | 100 | |
| European | 1 | 1 | 0 | 0 | 1 | 100 | |
| Continent of origin/exposure | .048 | ||||||
| South America | 4 | 3 | 0 | 0 | 4 | 100 | |
| Central America | 21 | 14 | 6 | 28.6 | 15 | 71.4 | |
| North America | 89 | 60 | 4 | 4.4 | 82 | 95.5 | |
| Africa | 5 | 3 | 0 | 0 | 5 | 100 | |
| Asia | 23 | 15 | 1 | 4.3 | 22 | 95.6 | |
| Middle East | 5 | 4 | 0 | 0 | 5 | 100 | |
| Europe | 1 | 1 | 0 | 0 | 1 | 100 | |
| Transplant status | .78 | ||||||
| Pretransplant | 77 | 52 | 9 | 11.7 | 68 | 88.3 | |
| Posttransplant | 72 | 48 | 5 | 6.9 | 67 | 93.1 | |
| Absolute eosinophil count, cells/mL | … | … | 212 (0–1620) | 82 (0–700) | .004 | ||
| MBP, ng/mL | … | … | 233.2 (45.2–504.5) | 217.5 (0–1273.0) | .57 | ||
| ECP, ng/mL | … | … | 616.2 (190.8–3257.8) | 718.2 (171.8–8464.1) | .30 | ||
| EPO, ng/mL | … | … | 0.0 (0–39.5) | 0.0 (0–39.5) | .62 | ||
| EDN, ng/mL | … | … | 46.4 (0–319.4) | 364.6) | .39 | ||
| IFABP, pg/mL | … | … | 1710 (719.1–2968) | 1731 (46.6–3969) | .70 |
Data are presented as number and percentage unless otherwise indicated.
Abbreviations: ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; EPO, eosinophil peroxidase; IFABP, intestinal fatty acid–binding protein; MBP, major basic protein.